QTTB Q32 Bio Inc.

Price (delayed)

$29.21

Market cap

$348.83M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$25.07

Enterprise value

$251.26M

homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.

Highlights
QTTB's debt has dropped by 63% since the previous quarter and by 36% year-on-year
QTTB's EPS has soared by 50% YoY and by 29% from the previous quarter
QTTB's equity has soared by 127% since the previous quarter but it has dropped by 68% year-on-year
QTTB's quick ratio has surged by 86% since the previous quarter but it is down by 49% year-on-year
Q32 Bio's gross profit has shrunk by 93% YoY and by 69% QoQ
Q32 Bio's revenue has plunged by 93% YoY and by 69% from the previous quarter

Key stats

What are the main financial stats of QTTB
Market
Shares outstanding
11.94M
Market cap
$348.83M
Enterprise value
$251.26M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.93
Price to sales (P/S)
82.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
709.78
Earnings
Revenue
$354,000
EBIT
-$83.09M
EBITDA
-$80.77M
Free cash flow
-$84.17M
Per share
EPS
-$25.07
Free cash flow per share
-$84.57
Book value per share
$15.1
Revenue per share
$0.36
TBVPS
$153.06
Balance sheet
Total assets
$152.33M
Total liabilities
$103.57M
Debt
$18.59M
Equity
$48.77M
Working capital
$105.09M
Liquidity
Debt to equity
0.38
Current ratio
4.19
Quick ratio
4.13
Net debt/EBITDA
1.21
Margins
EBITDA margin
-22,815.8%
Gross margin
100%
Net margin
-23,471.2%
Operating margin
-25,073.7%
Efficiency
Return on assets
-65.3%
Return on equity
-452.6%
Return on invested capital
-116.2%
Return on capital employed
-69.6%
Return on sales
-23,471.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

QTTB stock price

How has the Q32 Bio stock price performed over time
Intraday
-0.85%
1 week
13.3%
1 month
88.57%
1 year
56.04%
YTD
167%
QTD
62.73%

Financial performance

How have Q32 Bio's revenue and profit performed over time
Revenue
$354,000
Gross profit
$354,000
Operating income
-$88.76M
Net income
-$83.09M
Gross margin
100%
Net margin
-23,471.2%
The operating margin has plunged by 186% from the previous quarter
QTTB's net margin has dropped by 140% since the previous quarter
Q32 Bio's gross profit has shrunk by 93% YoY and by 69% QoQ
Q32 Bio's revenue has plunged by 93% YoY and by 69% from the previous quarter

Growth

What is Q32 Bio's growth rate over time

Valuation

What is Q32 Bio stock price valuation
P/E
N/A
P/B
1.93
P/S
82.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
709.78
QTTB's EPS has soared by 50% YoY and by 29% from the previous quarter
QTTB's equity has soared by 127% since the previous quarter but it has dropped by 68% year-on-year
The P/B is 14% above the 5-year quarterly average of 1.7
Q32 Bio's revenue has plunged by 93% YoY and by 69% from the previous quarter
The P/S is 29% less than the 5-year quarterly average of 116.2

Efficiency

How efficient is Q32 Bio business performance
QTTB's ROS has plunged by 140% from the previous quarter
Q32 Bio's return on invested capital has shrunk by 97% YoY and by 11% QoQ
The return on equity has dropped by 77% since the previous quarter
The ROA has plunged by 53% YoY but it has grown by 20% from the previous quarter

Dividends

What is QTTB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for QTTB.

Financial health

How did Q32 Bio financials performed over time
The total assets is 47% greater than the total liabilities
The total liabilities has soared by 125% YoY but it has contracted by 13% from the previous quarter
The current ratio has surged by 105% since the previous quarter but it has declined by 50% year-on-year
QTTB's debt is 62% smaller than its equity
QTTB's equity has soared by 127% since the previous quarter but it has dropped by 68% year-on-year
Q32 Bio's debt to equity has soared by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.